Back to search
Non-Muscle-Invasive Bladder Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Muscle-Invasive Bladder Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Non-Muscle-Invasive Bladder Cancer trials you may qualify forThis phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radia…
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T…
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have th…
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (…
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or…
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer o…
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1),…
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab…